Inicio
Autor Idrobo, Henry
|
|
Documentos disponibles escritos por este autor (2)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaReal World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry / Kenny Mauricio Gálvez Cárdenas ; Munevar, Isabel ; Idrobo, Henry ; Armando Mantilla, William ; Domingo Saavedra Ramírez
Título : Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Autor ; Munevar, Isabel, Autor ; Idrobo, Henry, Autor ; Armando Mantilla, William, Autor ; Domingo Saavedra Ramírez, Autor Fecha de publicación : 2025 Títulos uniformes : Clinical Lymphoma, Myeloma and Leukemia Idioma : Inglés (eng) Palabras clave : Dasatinib; Imatinib; Nilotinib; RENEHOC registry; Tyrosine kinase inhibitors Resumen : Background: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI efficacy, safety, and healthcare system challenges. Methods: We performed a descriptive analysis of the sociodemographic and clinical characteristics of 994 CML patients from the RENEHOC cohort in Colombia, who were treated over the past 20 years. Trends in first-line TKI use were assessed, and Kaplan-Meier survival curves were used to estimate EFS and OS. The log-rank test was used to compare survival curves between different first-line TKIs. Results: The analysis shows trends in the use of first-line TKIs over a 20-year period in Colombia, where, as in other countries, the use of second-generation TKIs in the first-line setting is gradually increasing. Despite the difficulties of the Colombian healthcare system, the results in terms of OS are excellent regardless of the first-line TKI; however, patients treated with imatinib switched lines significantly more often than those treated with second-generation TKIs (imatinib 58.7%, nilotinib 19.5%, dasatinib 29.3%). The median duration of treatment was significantly shorter with imatinib compared to dasatinib and nilotinib (4.08, 12.75 and not reached, respectively). Intolerance was the most common reason for switching in this cohort of patients. The median observation time for OS was 64.89 months (SD 60.15), with survival rates of 99.4% at 1 year, 97.7% at 3 years and 96.6% at 5 years. Conclusions: The results of this analysis show excellent results in terms of OS for patients with CML treated in Colombia over the last 20 years, despite the difficulties inherent in the health system. Patients treated with first-line imatinib had more frequent line changes. In general, intolerance was the most common reason for switching lines. Despite its retrospective nature, this study allows us to outline how treatment patterns in the country have changed over time. Continued efforts to include more centers and patients in prospective studies are essential to better understand the long-term effects of treatment and to improve adherence to guideline recommendations in clinical practice. © 2024 The Authors Mención de responsabilidad : Abello Polo, Virginia, Sossa, Claudia, Boquimpani, Carla, Salazar, Luis Antonio, Munevar, Isabel, Gómez, Rigoberto, Cuervo, Diana Marcela, Varón Jaimes, Carlos, Reyes, Jheremy, Idrobo, Henry, Omaña, Paola, Daza, Jorge, Pedraza Morales, Julian Eduardo, Agudelo López, Claudia, Quintero-Vega, Guillermo E., Correa Correa, Mario, Herrera, Juan Manuel, Mantilla, William Armando, Serrano, Juan Carlos, Rosales, Carmen, Gálvez Cárdenas, Kenny Mauricio, Bermúdez, Carlos, Saavedra Ramírez, Domingo, Alzate, Mauricio, Lobatón Ramírez, José Fernando Referencia : Clin Lymphoma Myeloma Leuk . 2024 Dec 28:S2152-2650(24)02464-9. DOI (Digital Object Identifier) : 10.1016/j.clml.2024.12.015 PMID : 39863461 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39863461/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Real World Evidence From 2 Decades of First-Line TKI Therapy in Chronic Myeloid Leukemia (CML): Insights From ACHO's RENEHOC Registry [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, Autor ; Munevar, Isabel, Autor ; Idrobo, Henry, Autor ; Armando Mantilla, William, Autor ; Domingo Saavedra Ramírez, Autor . - 2025.
Obra : Clinical Lymphoma, Myeloma and Leukemia
Idioma : Inglés (eng)
Palabras clave : Dasatinib; Imatinib; Nilotinib; RENEHOC registry; Tyrosine kinase inhibitors Resumen : Background: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI efficacy, safety, and healthcare system challenges. Methods: We performed a descriptive analysis of the sociodemographic and clinical characteristics of 994 CML patients from the RENEHOC cohort in Colombia, who were treated over the past 20 years. Trends in first-line TKI use were assessed, and Kaplan-Meier survival curves were used to estimate EFS and OS. The log-rank test was used to compare survival curves between different first-line TKIs. Results: The analysis shows trends in the use of first-line TKIs over a 20-year period in Colombia, where, as in other countries, the use of second-generation TKIs in the first-line setting is gradually increasing. Despite the difficulties of the Colombian healthcare system, the results in terms of OS are excellent regardless of the first-line TKI; however, patients treated with imatinib switched lines significantly more often than those treated with second-generation TKIs (imatinib 58.7%, nilotinib 19.5%, dasatinib 29.3%). The median duration of treatment was significantly shorter with imatinib compared to dasatinib and nilotinib (4.08, 12.75 and not reached, respectively). Intolerance was the most common reason for switching in this cohort of patients. The median observation time for OS was 64.89 months (SD 60.15), with survival rates of 99.4% at 1 year, 97.7% at 3 years and 96.6% at 5 years. Conclusions: The results of this analysis show excellent results in terms of OS for patients with CML treated in Colombia over the last 20 years, despite the difficulties inherent in the health system. Patients treated with first-line imatinib had more frequent line changes. In general, intolerance was the most common reason for switching lines. Despite its retrospective nature, this study allows us to outline how treatment patterns in the country have changed over time. Continued efforts to include more centers and patients in prospective studies are essential to better understand the long-term effects of treatment and to improve adherence to guideline recommendations in clinical practice. © 2024 The Authors Mención de responsabilidad : Abello Polo, Virginia, Sossa, Claudia, Boquimpani, Carla, Salazar, Luis Antonio, Munevar, Isabel, Gómez, Rigoberto, Cuervo, Diana Marcela, Varón Jaimes, Carlos, Reyes, Jheremy, Idrobo, Henry, Omaña, Paola, Daza, Jorge, Pedraza Morales, Julian Eduardo, Agudelo López, Claudia, Quintero-Vega, Guillermo E., Correa Correa, Mario, Herrera, Juan Manuel, Mantilla, William Armando, Serrano, Juan Carlos, Rosales, Carmen, Gálvez Cárdenas, Kenny Mauricio, Bermúdez, Carlos, Saavedra Ramírez, Domingo, Alzate, Mauricio, Lobatón Ramírez, José Fernando Referencia : Clin Lymphoma Myeloma Leuk . 2024 Dec 28:S2152-2650(24)02464-9. DOI (Digital Object Identifier) : 10.1016/j.clml.2024.12.015 PMID : 39863461 Derechos de uso : CC BY-NC-ND En línea : https://pubmed.ncbi.nlm.nih.gov/39863461/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002322 AC-2025-005 Archivo digital Producción Científica Artículos científicos Disponible
Título : Characteristics of patients with metastatic malignant melanoma in Colombia: Results of the Epidemiologic Registry of Malignant Melanoma REMMEC ACHO. Tipo de documento : documento electrónico Autores : Alicia Quiroga Echeverri, Autor ; Ospina Serrano, Aylen Vanessa, Autor ; Ortiz Díaz, Juan David, Autor ; Contreras, Fernando, Autor ; Munevar, Isabel, Autor ; Jiménez, Paola, Autor ; Armando Mantilla, William, Autor ; Idrobo, Henry, Autor ; Ramos, Pedro, Autor ; Arango Acevedo, Natalia, Autor Fecha de publicación : 2024 Títulos uniformes : Journal of Clinical Oncology Idioma : Inglés (eng) Resumen : Background: The features and prognostic factors of patients with metastatic malignant melanoma are not well established in our country. Our objective is to collect and analyze the characteristics of a cohort of Colombian patients. Methods: Analytical cohort study based on the Epidemiologic Registry of Malignant Melanoma in Colombia (REMMEC). Data were collected between January 2011 and December 2023. Patients older than 18 years with a confirmed diagnosis of advanced melanoma were included. Descriptive analysis of demographic and clinical characteristics and survival analysis using Cox regression and Kaplan-Meier models were performed. Results: 322 patients were included. Median age was 66.5 years (range 55-76), 56% (180) of patients were men, 87% (280) had advanced disease at diagnosis, most (82%) with non-brain metastases and 51% (164) with multiple organ involvement. Table 1. For firstline treatment, patients received single-agent immunotherapy (37.26%), doublet immunotherapy (10.25%), targeted therapy (9%), and chemotherapy (7.14%), while 29% received best supportive care BSC. In the second line, single agent immunotherapy 9.32%, targeted therapy (4.34%), doublet immunotherapy 3.42%, chemotherapy (5%) and 77% received BSC. In the third line, only 9% (29) of patients were able to receive any therapy. Median follow-up was 16 months (IQR 7-32), median progression-free survival (PFS) was 8 months (IQR 4-35) and median overall survival (OS) was 23 months (IQR 9-66). OS in the first-line setting with immunotherapy as monotherapy was 23 months (IQR 12-40) HR 0.40 P 0.035 and with doublet immunotherapy 16 months (IQR 8-28) HR 0.16 P 0.005 Clinical characteristics associated with lower median OS were brain metastasis (HR 1,95 P 0.001), ECOG 3-4 (HR 5,49 P 0.001) and multiple metastatic disease (HR 2,15 P 0.001). According to acral vs. non-acral histologic type, the median OS was 26 vs. 44 months, respectively (HR 1.30 P 0.26). Conclusions:In our cohort of patients with metastatic melanoma, we found clinical outcomes similar to those reported in the worldwide literature. It is necessary to continue the registry and follow up of patients to identify specific prognostic factors. Research Sponsor: None. Mención de responsabilidad : Aylen Vanessa Ospina Serrano, Juan David Ortiz Diaz, Fernando Contreras, Isabel Munevar, Paola Jimenez, William Armando Mantilla, Henry Idrobo, Pedro Ramos, Ray Manneh Kopp, Natalia Arango Acevedo, Daniel Andres Santa, Giovanna Patricia Rivas Tafurt, Alicia Quiroga, Claudia Vargas, Andres Yepes, Carmen Marcela Alcala Castro, Mauricio Lema, Isabel Chinchia, July Andrea Russi Noguera, Ivan Camilo Triana Referencia : Journal of Clinical Oncology Volume 42, Number 16_suppl DOI (Digital Object Identifier) : 10.1200/JCO.2024.42.16_suppl.e21530 Derechos de uso : CC BY-NC-ND En línea : https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.e21530 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Characteristics of patients with metastatic malignant melanoma in Colombia: Results of the Epidemiologic Registry of Malignant Melanoma REMMEC ACHO. [documento electrónico] / Alicia Quiroga Echeverri, Autor ; Ospina Serrano, Aylen Vanessa, Autor ; Ortiz Díaz, Juan David, Autor ; Contreras, Fernando, Autor ; Munevar, Isabel, Autor ; Jiménez, Paola, Autor ; Armando Mantilla, William, Autor ; Idrobo, Henry, Autor ; Ramos, Pedro, Autor ; Arango Acevedo, Natalia, Autor . - 2024.
Obra : Journal of Clinical Oncology
Idioma : Inglés (eng)
Resumen : Background: The features and prognostic factors of patients with metastatic malignant melanoma are not well established in our country. Our objective is to collect and analyze the characteristics of a cohort of Colombian patients. Methods: Analytical cohort study based on the Epidemiologic Registry of Malignant Melanoma in Colombia (REMMEC). Data were collected between January 2011 and December 2023. Patients older than 18 years with a confirmed diagnosis of advanced melanoma were included. Descriptive analysis of demographic and clinical characteristics and survival analysis using Cox regression and Kaplan-Meier models were performed. Results: 322 patients were included. Median age was 66.5 years (range 55-76), 56% (180) of patients were men, 87% (280) had advanced disease at diagnosis, most (82%) with non-brain metastases and 51% (164) with multiple organ involvement. Table 1. For firstline treatment, patients received single-agent immunotherapy (37.26%), doublet immunotherapy (10.25%), targeted therapy (9%), and chemotherapy (7.14%), while 29% received best supportive care BSC. In the second line, single agent immunotherapy 9.32%, targeted therapy (4.34%), doublet immunotherapy 3.42%, chemotherapy (5%) and 77% received BSC. In the third line, only 9% (29) of patients were able to receive any therapy. Median follow-up was 16 months (IQR 7-32), median progression-free survival (PFS) was 8 months (IQR 4-35) and median overall survival (OS) was 23 months (IQR 9-66). OS in the first-line setting with immunotherapy as monotherapy was 23 months (IQR 12-40) HR 0.40 P 0.035 and with doublet immunotherapy 16 months (IQR 8-28) HR 0.16 P 0.005 Clinical characteristics associated with lower median OS were brain metastasis (HR 1,95 P 0.001), ECOG 3-4 (HR 5,49 P 0.001) and multiple metastatic disease (HR 2,15 P 0.001). According to acral vs. non-acral histologic type, the median OS was 26 vs. 44 months, respectively (HR 1.30 P 0.26). Conclusions:In our cohort of patients with metastatic melanoma, we found clinical outcomes similar to those reported in the worldwide literature. It is necessary to continue the registry and follow up of patients to identify specific prognostic factors. Research Sponsor: None. Mención de responsabilidad : Aylen Vanessa Ospina Serrano, Juan David Ortiz Diaz, Fernando Contreras, Isabel Munevar, Paola Jimenez, William Armando Mantilla, Henry Idrobo, Pedro Ramos, Ray Manneh Kopp, Natalia Arango Acevedo, Daniel Andres Santa, Giovanna Patricia Rivas Tafurt, Alicia Quiroga, Claudia Vargas, Andres Yepes, Carmen Marcela Alcala Castro, Mauricio Lema, Isabel Chinchia, July Andrea Russi Noguera, Ivan Camilo Triana Referencia : Journal of Clinical Oncology Volume 42, Number 16_suppl DOI (Digital Object Identifier) : 10.1200/JCO.2024.42.16_suppl.e21530 Derechos de uso : CC BY-NC-ND En línea : https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.e21530 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002172 AC-2024-025 Archivo digital Producción Científica Artículos científicos Disponible
